We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+7.6%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$696M
AUM Growth
+$65M
Cap. Flow
+$38.4M
Cap. Flow %
5.52%
Top 10 Hldgs %
28.66%
Holding
112
New
8
Increased
33
Reduced
36
Closed
4

Top Buys

Rank Stock Value
1
NVCR icon
NovoCure
NVCR
+$15.7M
2
NDRM
NeuroDerm Ltd. Ordinary Shares
NDRM
+$12M
3
EXEL icon
Exelixis
EXEL
+$8.89M
4
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$8.34M
5
SNY icon
Sanofi
SNY
+$7.65M

Top Sells

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$10.6M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$9.58M
3
SUPN icon
Supernus Pharmaceuticals
SUPN
+$7.12M
4
ESPR
Esperion Therapeutics
ESPR
+$6.62M
5
BIIB icon
Biogen
BIIB
+$5.16M

Sector Composition

Rank Sector Weight
1 Healthcare 92.59%
2 Financials 0.93%
3 Technology 0.13%
4 Energy 0.1%
5 Consumer Discretionary 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XNCR icon
51
Xencor
XNCR
$1.48B
$5.48M 0.79%
259,556
-444
-0.2% -$9.95K
NXTM
52
DELISTED
NxStage Medical Inc.
NXTM
$5.36M 0.77%
213,901
+60,000
+39% +$1.49M
KYNB
53
Kyntra Bio
KYNB
$28.3M
$4.99M 0.72%
6,174
– –
ELV icon
54
Elevance Health
ELV
$84.9B
$4.98M 0.71%
26,468
-11,000
-29% -$1.98M
IOVA icon
55
Iovance Biotherapeutics
IOVA
$2.77B
$4.78M 0.69%
650,000
– –
IMMU
56
DELISTED
Immunomedics Inc
IMMU
$4.68M 0.67%
529,610
+50,000
+10% +$351K
ABT icon
57
Abbott
ABT
$187B
$4.62M 0.66%
95,000
-20,000
-17% -$905K
TMO icon
58
Thermo Fisher Scientific
TMO
$214B
$4.36M 0.63%
25,000
-15,000
-38% -$2.52M
CAH icon
59
Cardinal Health
CAH
$55.7B
$4.29M 0.62%
55,000
-20,000
-27% -$1.51M
COR icon
60
Cencora
COR
$63.2B
$4.25M 0.61%
45,000
-18,000
-29% -$1.6M
OMCL icon
61
Omnicell
OMCL
$1.64B
$4.06M 0.58%
94,231
-4,306
-4% -$179K
SAGE
62
DELISTED
Sage Therapeutics
SAGE
$3.98M 0.57%
50,000
-22,659
-31% -$1.64M
AERI
63
DELISTED
Aerie Pharmaceuticals
AERI
$3.94M 0.57%
75,000
-10,000
-12% -$466K
EW icon
64
Edwards Lifesciences
EW
$51.5B
$3.9M 0.56%
99,000
-81,000
-45% -$2.96M
EPZM
65
DELISTED
Epizyme, Inc
EPZM
$3.81M 0.55%
+252,136
New +$3.81M
RIGL icon
66
Rigel Pharmaceuticals
RIGL
$733M
$3.76M 0.54%
137,590
+9,390
+7% +$257K
DVA icon
67
DaVita
DVA
$11.5B
$3.56M 0.51%
55,000
– –
ARRY
68
DELISTED
Array Biopharma Inc
ARRY
$3.56M 0.51%
425,000
+75,000
+21% +$613K
RDUS
69
DELISTED
Radius Health, Inc.
RDUS
$3.39M 0.49%
75,000
– –
HOLX
70
DELISTED
Hologic
HOLX
$3.18M 0.46%
70,000
-80,000
-53% -$3.53M
ENDP
71
DELISTED
Endo International plc
ENDP
$3.1M 0.44%
277,303
-125,000
-31% -$1.47M
LH icon
72
Labcorp
LH
$25.6B
$3.08M 0.44%
23,280
-1,804
-7% -$221K
KERX
73
DELISTED
Keryx Biopharmaceuticals Inc
KERX
$3.07M 0.44%
425,111
– –
MGNX icon
74
MacroGenics
MGNX
$255M
$3.06M 0.44%
175,000
– –
CHRS icon
75
Coherus Oncology
CHRS
$194M
$2.42M 0.35%
168,872
+57,515
+52% +$1.11M
1 2
3
4 5

Similar funds

PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
OC
Oarsman Capital Milwaukee, Wisconsin $806M AUM 19.96% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return

Rhenman & Partners Asset Management's Q2 2017 Portfolio in Review

As of Q2 2017, Rhenman & Partners Asset Management held 112 positions worth $696M, up 10% from $631M the previous quarter. Its ten largest holdings account for 29% of the portfolio.

Rhenman & Partners Asset Management deployed $38.4M of net new capital in Q2 2017, opening 8 new positions and adding to 33 existing holdings. Its largest new stake was NovoCure: 1,216,314 shares worth $21M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 92% a quarter earlier, followed by Financials and Technology.

On the sell side, the largest reduction was Amgen, an estimated $10.6M trimmed.

  • Rhenman & Partners Asset Management's largest Q2 2017 buy was NovoCure: 1,216,314 shares worth $21M.
  • Rhenman & Partners Asset Management added most to Exelixis in Q2 2017, an estimated $8.89M increase.
  • Rhenman & Partners Asset Management's biggest Q2 2017 reduction was Amgen, cutting an estimated $10.6M.
  • Rhenman & Partners Asset Management fully exited Viatris in Q2 2017, selling an estimated $3.51M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 29% of its $696M portfolio in Q2 2017.
  • Rhenman & Partners Asset Management opened 8 new positions and closed 4 in Q2 2017.
  • Rhenman & Partners Asset Management's portfolio value rose 10% quarter-over-quarter to $696M.

Based on Rhenman & Partners Asset Management's 13F filing for Q2 2017, filed 11 Jul 2017.